Darrell Pardi, MD

Professor of Medicine
Mayo Clinic

Disclosure(s): AMT, Inc: Grant/Research Support; Boehringer Ingelheim: Grant/Research Support; Exe GI: Grant/Research Support; Immunic: Advisor/Consultant; Lilly: Advisor/Consultant; Rise Therapeutics: Advisor/Consultant, Grant/Research Support; Seres Therapeutics: Advisor/Consultant, Expert Testimony; Vedanta: Advisor/Consultant, Grant/Research Support

Poster(s):

• (P-127) Safety and Efficacy of Fecal Microbiota Spores, Live-brpk (Formerly SER-109) in Patients with Recurrent Clostridioides difficile Infection (CDI): Subgroup Analysis by Number of Prior CDI Recurrences from an Integrated Analysis of Phase 3 Trials
  Thursday, October 17, 2024

  12:15 PM - 1:30 PM US PT